These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 10235612)

  • 21. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study.
    Bjøro K; Bell H; Myrvang B; Skaug K; Raknerud N; Sandvei P; Størseth S; Ritland S; Lund-Tønnesen S; Bucher A; Hellum KB
    Scand J Gastroenterol; 2002 Mar; 37(3):344-9. PubMed ID: 11916198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
    Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q
    Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial.
    Salmerón J; Ruiz-Extremera A; Torres C; Rodríguez-Ramos L; Lavín I; Quintero D; Palacios A
    Liver; 1999 Aug; 19(4):275-80. PubMed ID: 10459624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring response during a randomised controlled trial of escalating interferon dose for chronic hepatitis C infection: predictive value of quantitative and qualitative HCV RNA assays.
    Schinkel J; Kroes AC; Wagtmans MJ; Lamers CB; van Hoek B
    J Clin Virol; 2001 Aug; 22(1):61-71. PubMed ID: 11418354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.
    Buti M; Olive G; Stalgis C; Esteban R; Guardi J
    Dig Dis Sci; 2000 Apr; 45(4):685-9. PubMed ID: 10759235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained virological response in chronic hepatitis C patients after a 6- and a 36-month interferon-alpha2b treatment schedule: a multicenter, randomized, controlled study.
    Damen M; Weegink CJ; Mauser-Bunschoten EP; Cuypers HT; Hermus MC; Sillekens P; Haan E; van den Berg HM; Bresters D; Lelie PN; Chamuleau RA; Reesink HW
    Scand J Gastroenterol; 2001 Jan; 36(1):97-104. PubMed ID: 11218246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).
    Poynard T; Marcellin P; Lee SS; Niederau C; Minuk GS; Ideo G; Bain V; Heathcote J; Zeuzem S; Trepo C; Albrecht J
    Lancet; 1998 Oct; 352(9138):1426-32. PubMed ID: 9807989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective study of interferon therapy modified by pre-treatment viral load in cirrhotic patients. Tokyo-Chiba Hepatitis Research Group.
    Shiratori Y; Moriyama M; Imazeki F; Ohkubo H; Tanaka N; Arakawa Y; Yoshida H; Yokosuka O; Shibuya A; Matsuzaki K; Hashimoto E; Hayashi N; Hirata K; Ohashi Y; Omata M
    Liver; 2000 Jul; 20(4):271-80. PubMed ID: 10959805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Retreatment options for patients with chronic hepatitis C].
    Hrstić I; Ostojić R; Vucelić B
    Acta Med Croatica; 2009 Dec; 63(5):417-22. PubMed ID: 20198901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study.
    Vogel W; Graziadei I; Umlauft F; Datz C; Hackl F; Allinger S; Grünewald K; Patsch J
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):81S-85S. PubMed ID: 9011481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
    Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M;
    Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C.
    Davis GL
    Semin Liver Dis; 1999; 19 Suppl 1():49-55. PubMed ID: 10349692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA.
    Shiratori Y; Yokosuka O; Nakata R; Ihori M; Hirota K; Katamoto T; Unuma T; Okano K; Ikeda Y; Hirano M; Kawase T; Takano S; Matsumoto K; Ohashi Y; Omata M
    Hepatology; 1999 May; 29(5):1573-80. PubMed ID: 10216145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype.
    Fried MW; Shiffman M; Sterling RK; Weinstein J; Crippin J; Garcia G; Wright TL; Conjeevaram H; Reddy KR; Peter J; Cotsonis GA; Nolte FS
    Am J Gastroenterol; 2000 Nov; 95(11):3225-9. PubMed ID: 11095346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized controlled trial of lymphoblastoid interferon alpha for chronic hepatitis C (comparison of 9-MU and 6-MU doses). IFN Treatment Group of Affiliated Hospitals of the Third Department of Internal Medicine at Nagoya University School of Medicine.
    Yoshioka K; Yano M; Kusakabe A; Hirofuji H; Fuji A; Kuriki J; Arao M; Murase K; Kidokoro R; Kakumu S
    Am J Gastroenterol; 1999 Jan; 94(1):164-8. PubMed ID: 9934749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy.
    Bekkering FC; Brouwer JT; Leroux-Roels G; Van Vlierberghe H; Elewaut A; Schalm SW
    J Hepatol; 1998 Jun; 28(6):960-4. PubMed ID: 9672170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic hepatitis C long-term responders to human leukocyte interferon-alpha therapy: persistence of a sustained biochemical and virological response during 5 years of surveillance.
    Morisco F; Tuccillo C; Iasevoli P; Sessa G; Brunasso G; Caporaso N
    Eur J Gastroenterol Hepatol; 1998 May; 10(5):399-403. PubMed ID: 9619386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy.
    Hass HG; Kreysel C; Fischinger J; Menzel J; Kaiser S
    World J Gastroenterol; 2005 Sep; 11(34):5342-6. PubMed ID: 16149143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.